AstraZeneca laboratory announced that its coronavirus vaccine is highly effective against Beta and Delta variants

Anglo-Swedish pharmaceutical AstraZeneca reported this Friday that your Vaxzevria vaccine is, after a dose, “Very effective” in preventing severe cases of COVID-19 and hospitalizations caused by beta and delta variants of the coronavirus.

The study, carried out in Canada among 69,533 infected with SARS-CoV-2 between December 2020 and May 2021, indicated that the preparation is 82% effective, after a puncture, in the face of “hospitalization or death” caused by the beta / gamma variant, first identified in South Africa (B.1.351).

In addition, achieves 87% effectiveness against “hospitalization or death” caused by the delta variant (B.617.2, also known as “India”), and 90% against alpha (B.1.1.7 or “Kent”, referring to the English county where it was first detected).

Of the total number of people analyzed for this study by the Canadian Immunization Research Network (IRIN), 40,828 (9.7%) were positive for one of the variants considered “worrying”, while 28,705 (6.8%) were infected with other variants of the coronavirus.

The analysis warns that there has not yet been enough time to report how well Vaxzevria will work after the second dose, even if “other studies have shown increased efficacy“After the second puncture.

“The effectiveness of Vaxzevria after one dose against hospitalization or death was similar to that of other vaccines tested in the study.AstraZeneca said in a statement.

The executive vice-president of R&D of the Anglo-Swedish company, Led Pangalos, underlined that this preparation, analyzed with “real world data“, offers “a high level of protection” before “more serious forms“COVID-19, even after”a single dose”.

“It is essential that we continue to protect as many people as possible around the world in order to anticipate this deadly virus,” added the official.

Paraguay negotiates purchase of 500,000 doses of AstraZeneca

Paraguay negotiates with AstraZeneca the purchase of 500,000 vaccines produced in Mexico, with the intention that they will be delivered to the South American country during the last quarter of 2021, as the Paraguayan Ministry of Foreign Affairs reported on Thursday in a statement.

The advance was announced after talks between AstraZeneca Mexico CEO Sylvia Varela and Paraguayan Foreign Minister Euclides Acevedo.

Acevedo is in Mexico to participate this Saturday in the XXI Meeting of Foreign Ministers of the Community of Latin American and Caribbean States (Celac).

In its statement, the Foreign Ministry argued that Varela and Acevedo also spoke of “possibility of establishing a supply schedule” for 2022 and 2023, in quantities yet to be defined which will depend on the Expanded Vaccination Plan.

Paraguay will send the technical, health and legal documentation required to complete the purchase with AstraZeneca Mexico.

The South American country began its coronavirus vaccination plan on February 22, and in those five months it has vaccinated 1,740,614 people with at least one dose, according to the 6:00 p.m. deadline.

(With information from EFE)

KEEP READING: